Opioid analgesics — outpatient prescribing limits and prior authorization
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.38 alerts
Get alerted when Policy 05.02.38 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and quantity/duration limits for outpatient opioid analgesic prescriptions (acute and first fills) for Wellmark Blue Cross and Blue Shield members in Iowa; exclusions apply for cancer, sickle cell disease, palliative care, and hospice. It informs pharmacy claim edits and prior authorization requirements.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Acute opioid prescribing and first-fill criteria
Covered when ALL of the following are met
Applies to listed opioid products with their labeled indications.
Reserve opioids for patients who have failed or cannot use alternatives.
Claims rejecting prompts PA submission per policy; initial quantity limits apply when ≤7 days.
Exemptions require diagnosis codes or member profile evidence to trigger screenout.
inv-02: Prior Authorization Coverage Criteria
Covered with prior authorization when the following grouping logic is met:
PA will route these patients to the prescription benefit administered by CVS Caremark.
Applies when chronic pain criteria and monitoring plans are documented.
Quantity limits may still apply; PA criteria evaluated by PA unit.
inv-03: Initial quantity limit logic
Coverage and initial quantity logic for IR opioids for patients without recent cancer/SCD/palliative/hospice indicators
See the Opioid Analgesics IR Quantity Limits Chart for exact monthly and 3‑month limits and MME equivalents.
inv-04: Exemptions (cancer, SCD, palliative/hospice)
Exceptions to acute duration limits
When qualifying indicators are present, drug will be paid under the prescription benefit administered by CVS Caremark and acute limits are waived.
inv-05: Coverage by pain acuity and dosage guidance
Coverage and duration guidance by pain acuity:
Short courses recommended; system enforces initial quantity limit and triggers PA if exceeded.
Clinicians should reassess benefits and risks periodically and consider tapering if harms outweigh benefits.
Dose escalation requires reassessment and justification; PA required for quantities exceeding initial limits.
The program does not apply — meaning neither acute pain duration limits nor quantity limits will be enforced — when the member has evidence of cancer, sickle cell disease, palliative care, or hospice. Qualifying evidence includes a drug in the member's prescription claims within the past 365 days indicating treatment for cancer or sickle cell disease, submission of a prescription claim with an ICD-10 diagnosis code for cancer, sickle cell disease, or palliative care, an ICD-10 diagnosis for cancer or palliative care present in the member health profile within the past 365 days, a history of an ICD-10 code for sickle cell disease in the member profile, or a prescription claim submitted with a hospice patient residence code.
Acute pain duration and quantity limits are not applied when the patient’s claims or claim submission indicate cancer or sickle cell disease or when palliative care or hospice status is documented. Specifically, if the member has a qualifying drug claim for cancer or sickle cell disease in the past 365 days, if a prescription claim includes an ICD‑10 code for cancer, sickle cell disease, or palliative care, if the member profile contains an ICD‑10 code for cancer or palliative care in the past 365 days, if the member profile contains any history of sickle cell disease ICD‑10 codes, or if a hospice residence code is present on the prescription claim, the acute limits and quantity limits will not apply and the drug will be paid under the prescription benefit administered by CVS Caremark.
Certain short‑term, acute‑use opioid products are treated so that the 30‑day limit equals the 90‑day limit; the intent is that these agents be dispensed as monthly fills only, not as 3‑month supplies (for example, mail‑order should still be limited to one‑month fills). Where noted in the limits chart, the initial and post‑limit monthly caps are set equivalently to prevent dispensing of 3‑month supplies for short‑term acute indications.
Use of meperidine for oral therapy and for chronic pain is discouraged due to safety concerns with its metabolite, normeperidine. For this reason, the policy limits meperidine to short supplies: the initial quantity limit corresponds to a 72‑hour supply (to allow for weekend coverage if needed) and the post‑limit quantity corresponds to a 96‑hour supply, permitting one additional day of therapy beyond the initial limit.
Chronic use of meperidine is considered unsafe because of accumulation of the metabolite normeperidine, which can cause central excitatory toxicity. The policy therefore discourages prolonged or repeated dosing beyond short‑term supplies; extended or chronic meperidine therapy is not supported and limits are intentionally set to brief courses (initial 72 hours, post‑limit 96 hours).
Coding and Lookback Definitions
| ICD-10 (unspecified) | Diagnosis codes indicating cancer, sickle cell disease, palliative care, or hospice residence — required on claim to trigger exceptions/screenout |
| No codes listed |
Provider Actions and Prior Authorization
PA required for >7‑day initial fills
Prior authorization is required when an opioid first fill (defined as no ≥7‑day supply of an IR or ER opioid in prescription claim history during the past 90 days) is submitted for more than a 7‑day supply; such claims will reject and PA criteria will be applied to requests for additional quantities.
- First‑fill defined by 90‑day lookback; if incoming prescription >7 days the claim will reject and member may receive a 7‑day supply or PA can be submitted.
- PA requests will be evaluated using the policy's prior authorization criteria.
PA required for excess days or MME
Prior authorization is required when the initial supply exceeds the acute 7‑day limit for first‑fill patients or when the requested quantity would exceed the initial quantity limit (monthly amount corresponding to ≤90 MME/day); requests above initial limits (up to quantities corresponding to ≤200 MME/day) require PA and may be subject to additional review or denial.
- Initial quantity limits correspond to ≤90 MME/day without PA; post‑limit quantities (up to ≤200 MME/day) require PA.
- Acute duration limit logic is applied first; if exceeded for a first‑time 90‑day period, PA is required.
PA required when initial prescription >7 days for opioid‑naïve patients
If an opioid‑naïve patient (no ≥8‑day IR/ER opioid fill in the past 90 days) is prescribed >7 days supply, the claim will reject and prior authorization is required; PA criteria will then be applied to the request.
- Policy uses an 8‑day lookback in some screening logic to identify opioid‑naïve patients; claims >7 days for such patients will reject.
- PA unit evaluates submitted requests per the policy coverage criteria.
PA required for quantities above initial IR limit
Prior authorization is required when a request exceeds the immediate‑release opioid initial quantity limit (the monthly quantity corresponding to ≤90 MME/day); the system will reject requests above the initial limit with a message that a PA is required and PA unit criteria will be applied.
- Initial quantity limits are set to encompass usual starting dosages and correspond to ≤90 MME/day.
- If requesting more than the initial limit, the claim/system will reject and prompt PA submission.
Conservative treatment expectation — document alternatives tried
Reserve opioid therapy for patients who have not tolerated or not obtained adequate analgesia from nonopioid analgesics or opioid combination products; document intolerance or inadequate analgesia from nonopioid therapies when feasible.
- Policy repeatedly states opioids should be reserved for patients when alternative treatments are not tolerated or not expected to provide adequate analgesia.
- When feasible, document prior nonopioid treatment attempts or intolerance to support use of opioids.
Account for accumulation across like unit‑limit drugs
Quantity limits for IR opioids accumulate across all drugs that share the same unit‑limit grouping (e.g., 30‑unit drugs accumulate together); account for accumulation when evaluating allowed supply.
- Opioid quantity limits should accumulate across all drugs of the same unit limit (30‑unit, 60‑unit, etc.).
Conservative prescribing and regular reassessment required
Prescribe the lowest effective opioid dosage for the shortest duration necessary and reassess risks and benefits regularly; reevaluate higher‑risk patients more frequently and reassess benefits/risks within 1–4 weeks of initiation or dose escalation and routinely every ~3 months.
- Use lowest effective dose; initial limits set to reflect usual starting dosages and limit exposures.
- Clinicians should evaluate risks before and periodically during therapy and reassess within 1–4 weeks of start or escalation and regularly thereafter.
Document exemptions with claims history or ICD‑10/hospice codes
Exemptions from acute pain duration or quantity limits require evidence in claims history or submission of an ICD‑10 diagnosis code indicating cancer, sickle cell disease, or palliative care, or a hospice patient residence code, or presence of those diagnoses in the member health profile within the past 365 days.
- If claims/member profile show cancer or SCD drug fills or ICD‑10 diagnosis codes (past 365 days), acute duration and quantity limits do not apply.
- A prescription claim submitted with an ICD‑10 for cancer, SCD, or palliative care or with a hospice residence code will route payment under the prescription benefit.
Submit diagnosis or hospice residence codes to trigger exceptions
Include relevant ICD‑10 diagnosis codes (cancer, sickle cell disease, palliative care) or a hospice residence code on the prescription claim to trigger screenout logic and avoid application of acute duration/quantity limits.
- Submit ICD‑10 diagnosis or hospice residence code on the claim when clinically applicable to ensure limits are not applied.
- Screenout logic uses claim ICD‑10 or member profile diagnosis codes within a 365‑day lookback.
Claims and diagnosis documentation affect benefit routing and limits
Documentation or claim history showing prior opioid fills, cancer, sickle cell disease, palliative/hospice status, or recent cancer/SCD drug fills determines benefit routing and whether acute limits apply; absence of these indicators will subject the claim to first‑fill and initial quantity logic.
- Evidence of cancer/SCD drug fills or relevant ICD‑10s in the past 365 days or hospice residence codes routes the claim to the prescription benefit and exempts limits.
- If no such evidence and no recent opioid fills, first‑fill rules (7‑day limit and PA triggers) apply.
Sickle cell disease — documentation exempts acute limits
For members identified by PA criteria as having sickle cell disease, acute pain duration limits and post‑limit quantities do not apply if there is evidence of recent SCD drug prescription claims or diagnosis codes in claims or member health profile.
- NHLBI guidance cited; when SCD evidence is present in claims/profile, duration and post‑limit quantity limits are not applied.
- Submit SCD drug claim history or ICD‑10 codes to demonstrate the exception.
Claim rejection for >7‑day first fills — reject then PA option
Claims for an opioid first fill exceeding a 7‑day supply will reject; the member can receive a 7‑day supply or the provider must submit a prior authorization for additional quantities.
- System will present a reject message indicating the option to dispense 7 days or submit PA.
- Acute pain duration limit (7 days) is enforced first; PA is required for additional days.
System reject for first‑fill >7 days — PA required for extras
Claims for an IR/ER opioid exceeding a 7‑day supply on a patient's first‑fill (no ≥7–8 day opioid in past 90 days) will reject and require submission of a prior authorization for additional quantities.
- Policy uses 7‑ and 8‑day thresholds in different logic sections to identify first‑fill status.
- If the patient exceeds 7 days of therapy for the first time in a 90‑day period, PA must be submitted for additional quantities.
PA required for requests >90 MME/day (post‑limit up to 200 MME/day)
Requests for quantities above the initial limit corresponding to >90 MME/day (up to quantities corresponding to ≤200 MME/day) require prior authorization and may be subject to additional review or denial.
- Initial IR quantity limits correspond to ≤90 MME/day without PA; post‑limit quantities up to 200 MME/day require PA and review.
- PA evaluation uses the policy coverage criteria including clinical justification and exemptions.
Initial fill >7 days for patients without recent opioid history will reject
If a patient without at least an 8‑day opioid fill in the past 90 days is prescribed an initial fill >7 days, the claim will reject and prior authorization is required; PA criteria will be applied to evaluate the request.
- Initial fill definitions use 7‑ and 8‑day lookbacks in different places; claims >7 days for those without ≥8‑day history will reject.
- PA must be submitted for approval of additional days.
System rejection for quantities above initial IR limit — PA message shown
When a request exceeds the immediate‑release opioid drug initial quantity limit, the system will reject the claim with a message indicating that a prior authorization is required; providers must submit PA for coverage of quantities above the initial limit.
- System enforces initial quantity limits set to encompass usual starting dosages; requests above initial limits prompt PA.
- PA unit applies the prior authorization criteria to submitted requests.
Conservative Treatment Requirements
Background
Opioid analgesics are indicated for management of acute or chronic pain when alternatives are inadequate and the severity of pain justifies opioid therapy. Because opioids carry risks of addiction, misuse, and other harms, this policy emphasizes reserving opioids for patients who have not tolerated or not achieved adequate analgesia with nonopioid options and prescribing the lowest effective dose for the shortest necessary duration, with regular reassessment of benefits and risks.
Definitions
Frequency and Quantity Limits
Imaging and Assessment
Pain assessment — no imaging requirement
No action required by policy for pain assessment imaging — the policy states no biomarkers or imaging studies validate pain; management is guided by patient report.
Not Covered
Long‑term chronic opioid therapy without documentation of ongoing reassessment and without evidence that benefits outweigh risks is not supported by this policy. Clinicians are expected to reassess patients after initiation or dose escalation (within 1 to 4 weeks) and routinely thereafter; absence of documented reassessment and continued chronic opioid use without justification will render long‑term therapy not covered under the guidance of this policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.